BioSpace News Archive

Business

J&J Announces Quarterly Dividend for First Quarter 2018

J&J today announced that its Board of Directors has declared a cash dividend for the first quarter of 2018 of $0.84 per share on the company’s common stock.

January 2, 2018
·
1 min read
Biotech Beach

KARL STORZ Receives Innovative Technology Designation From Vizient for VITOM 3D System

KARL STORZ announced that its VITOM 3D system for visualization in microsurgery and open surgical procedures has received a 2017 Innovative Technology designation from Vizient, Inc.

January 2, 2018
·
4 min read
Business

Aerie Pharmaceuticals Announces Appointment of Julia Williams as Director of Medical Affairs

Aerie announced the appointment of Julia Williams as Director of Medical Affairs, reporting to John Maltman, Ph.D., Aerie’s Vice President of Medical Affairs.

January 2, 2018
·
5 min read
Deals

Nuvo Pharma Acquires Global Ex-U.S. Product Rights and Existing Royalty Streams to Resultz From Piedmont Pharma

The transaction includes existing royalty streams in the Royalty Markets and all product and intellectual property rights in the Territory.

January 2, 2018
·
7 min read
FDA

Merck’s KEYTRUDA (pembrolizumab) Approved in Japan for Use in the Treatment of Patients with Urothelial Carcinoma That is Unresectable with Radical Surgery Who Have Progressed Following Cancer Chemotherapy

today announced that KEYTRUDA (pembrolizumab), the company’s anti-PD-1 therapy, has been approved by the Japanese Ministry of Health, Labor and Welfare (MHLW) for the treatment of patients with radically unresectable urothelial carcinoma who progressed after cancer chemotherapy.

January 2, 2018
·
26 min read
Pharm Country

Soligenix Announces U.S. Patent Issuance for Use of Dusquetide in Oral Mucositis

Soligenix announced today that the U.S. Patent Office has granted the patent entitled “Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis.”

January 2, 2018
·
9 min read
Galmed Pharma Raised Gross Proceeds of $11.6M Under ATM Programs During December 2017

The Company issued 1,368,667 ordinary shares under its former and existing ATM programs during December 2017 at an average sale price of $8.45 per share.

January 2, 2018
·
5 min read
Business

LogicBio Therapeutics Announces Expansion of Leadership Team Through Multiple Key Hires

LogicBio Therapeutics today announced the expansion of its leadership team with the appointment of four seasoned industry leaders

January 2, 2018
·
3 min read
Biotech Bay

SI-BONE Announces Blue Cross Blue Shield Association Raises Clinical Evidence Rating for MIS SI Joint Fusion

SI-BONE announced that BCBSA, after an extensive review of all existing peer-reviewed published clinical safety and effectiveness data, has assigned triangular implants for SI joint fusion a “Moderate” quality evidence recommendation.

January 2, 2018
·
5 min read
Biotech Bay

Bay Area’s DNAnexus Scores $58M to Accelerate Expansion

The cash will support expansion in translational informatics, clinical trials, and broadened use of biomedical data.

January 2, 2018
·
3 min read